In this issue:
Pembrolizumab effective in MMR-deficient CRC
FOLFIRI + bevacizumab as second-line therapy in mCRC
Molecular alterations in mCRC may define therapy choices
Evaluating early therapeutic response in mCRC
Liquid biopsy facilitates mutational analysis and therapy choice
Adding oxaliplatin to radiation and pre- and postoperative 5-FU
Assessing adjuvant chemotherapy for rectal carcinoma
Postoperative chemotherapy in rectal cancer given preoperative CRT
mFOLFOX6 after CRT and before total mesorectal excision
Serrated polyps may be precursors of CRC
Please login below to download this issue (PDF)